NM
Newtyn Management’s Theravance Biopharma TBPH Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $54.6M | Buy |
4,950,000
+192,597
| +4% | +$2.12M | 8.27% | 2 |
|
|
2025
Q1 | $42.5M | Hold |
4,757,403
| – | – | 6.72% | 6 |
|
|
2024
Q4 | $44.8M | Buy |
4,757,403
+258,337
| +6% | +$2.43M | 7.8% | 3 |
|
|
2024
Q3 | $36.3M | Buy |
4,499,066
+2,374,363
| +112% | +$19.1M | 5.57% | 5 |
|
|
2024
Q2 | $18M | Buy |
2,124,703
+480,773
| +29% | +$4.08M | 3.38% | 12 |
|
|
2024
Q1 | $14.7M | Sell |
1,643,930
-256,070
| -13% | -$2.3M | 2.94% | 12 |
|
|
2023
Q4 | $21.4M | Buy |
1,900,000
+58,440
| +3% | +$657K | 4.19% | 7 |
|
|
2023
Q3 | $15.9M | Buy |
1,841,560
+201,104
| +12% | +$1.74M | 3.92% | 9 |
|
|
2023
Q2 | $17M | Buy |
1,640,456
+109,441
| +7% | +$1.13M | 4.01% | 10 |
|
|
2023
Q1 | $16.6M | Buy |
1,531,015
+81,015
| +6% | +$879K | 3.26% | 7 |
|
|
2022
Q4 | $16.3M | Sell |
1,450,000
-1,045,860
| -42% | -$11.7M | 3.36% | 10 |
|
|
2022
Q3 | $25.3M | Buy |
2,495,860
+458,035
| +22% | +$4.64M | 5.56% | 5 |
|
|
2022
Q2 | $18.5M | Buy |
2,037,825
+662,825
| +48% | +$6.01M | 3.5% | 10 |
|
|
2022
Q1 | $13.1M | Buy |
1,375,000
+375,000
| +38% | +$3.59M | 3.15% | 14 |
|
|
2021
Q4 | $11.1M | Buy |
1,000,000
+902,045
| +921% | +$9.97M | 2.93% | 17 |
|
|
2021
Q3 | $725K | Buy |
+97,955
| New | +$725K | 0.19% | 36 |
|
|
2020
Q1 | – | Sell |
-173,300
| Closed | -$4.49M | – | 57 |
|
|
2019
Q4 | $4.49M | Buy |
173,300
+109,619
| +172% | +$2.84M | 0.41% | 29 |
|
|
2019
Q3 | $1.24M | Buy |
+63,681
| New | +$1.24M | 0.12% | 32 |
|